The present invention also provides the use of such a peptide or composition in the manufacture of a medicament to suppress, reduce or prevent the development of factor VIII inhibitor antibodies.

The present invention also provides the use of such a peptide or composition in the manufacture of a medicament for treating haemophilia in a subject.

~~The present invention also provides~~Also disclosed is a method for suppressing, preventing or reducing the development of Factor VIII inhibitor antibodies in a subject, which comprises the step of administration of such a peptide or composition to the subject.

The subject may be deficient in FVIII. In particular the subject may have haemophilia A, and may be, or be about to, undergo factor VIII replacement therapy.

Alternatively the subject may have, or be at risk from contracting, acquired haemophilia.

Factor VIII inhibitors are found more frequently in individuals expressing HLA-DR2. The subject treated by the method of the invention may therefore be HLA-DR2 positive.

DESCRIPTION OF THE FIGURES

Figure 1: Solubility of modified FVIII peptides

A total of 32 peptides were tested: 16 of which were based on the FVIII peptide PRCLTRYYSSFVNME ("PRCLT") (SEQ ID No. 1,2,3,4,5,6,7,8,9,10,11,12,13); and 16 of which were based on the FVIII peptide DNIMVTFRNQASRPY ("DNIMV") (SEQ ID No. 17,18,19,20,21,22,23,245,26,27,28,29,30,31,32). Their solubility was tested relative to an unrelated control peptide (4Y) which is known to be sufficiently soluble for application as a tolerising antigen. In the diagram, green represents a peptide which is at least as soluble as 4Y, orange represents a peptide which is not quite as soluble as 4Y but is fairly close, and red represents a peptide which is not as soluble as 4Y. Peptides coded green were as soluble as control peptide 4Y, peptides coded red were poorly soluble, and one peptide coded amber had intermediate solubility.

KKGPRCLTRYYSSFVNMEGKE (SEQ ID No. 2)

KKGPRCLTRYYSSFVNMEGEK (SEQ ID No. 3)

EEGPRCLTRYYSSFVNMEGKK (SEQ ID No. 5)

EEGPRCLTRYYSSFVNMEGEK (SEQ ID No. 7)

KEGPRCLTRYYSSFVNMEGKK (SEQ ID No. 9)

KEGPRCLTRYYSSFVNMEGKE (SEQ ID No. 10)

KEGPRCLTRYYSSFVNMEGEK (SEQ ID No. 11) and

EKGPRCLTRYYSSFVNMEGKK (SEQ ID No. 13).

3. A composition comprising a plurality of peptides, including one or more peptide(s) according to claim 1 or 2.

4. A composition according to claim 3, which comprises at least one peptide according to claim 1 and at least one peptide according to claim 2.

5. A composition according to claim 4, which comprises a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17

6. A peptide according to claim 1 or 2, or a composition according to any of claims 3 to 5, for use in suppressing or preventing the production of factor VIII inhibitor antibodies *in vivo*.

7. The use of a peptide according to claim 1 or 2, or a composition according to any of claims 3 to 5, in the manufacture of a medicament to suppress or prevent the production of factor VIII inhibitor antibodies *in vivo* or in a subject.

~~8. A method for suppressing or preventing the production of factor VIII inhibitor antibodies in a subject, which comprises the step of administration of a peptide according to claim 1 or 2, or a composition according to any of claims 3 to 5, to the subject.~~

~~98~~. ~~A method for treating haemophilia in a subject which comprises the step of administration of~~ The use of a peptide according to claim 1 or 2, or a composition according to any of claims 3 to 5, ~~to the subject~~ in the manufacture of a medicament for treating haemophilia in a subject.

~~109~~. ~~A~~ The ~~method~~ use according to claim ~~8~~ 7 or ~~98~~, wherein the subject has haemophilia A, and is undergoing, or is about to undergo, factor VIII replacement therapy and/or FVIII by-passing therapy.

~~1110~~. ~~A method~~ The use according to claim ~~8~~ 7 or ~~98~~, wherein the subject has, or is at risk from contracting, acquired haemophilia.

~~1211~~. ~~A method~~ The use according to any of claims ~~8~~ 7 to ~~1110~~, wherein the subject is HLA-DR2.